ChemAesthetic NAD+ 500mg vial kit

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell, functioning as a critical electron carrier in oxidative phosphorylation and as a substrate for enzymes involved in DNA repair, gene expression regulation, and cellular stress responses. Declining NAD+ levels with age have become a major focus of longevity research.

Biochemistry and Mechanism

NAD+ exists in an oxidised (NAD+) and reduced (NADH) form, shuttling electrons between metabolic reactions. In glycolysis and the citric acid cycle, NAD+ accepts electrons to become NADH; in the electron transport chain, NADH donates these electrons to generate ATP. Beyond bioenergetics, NAD+ is the obligate substrate for three enzyme families with broad cellular significance:

• Sirtuins (SIRT1–7): NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis, stress resistance, and metabolic homeostasis. SIRT1 and SIRT3 in particular are implicated in lifespan extension observed in caloric restriction models.
• PARPs (Poly-ADP-ribose polymerases): Consume NAD+ during DNA damage responses. PARP1 activity increases with oxidative stress, creating high NAD+ demand during genotoxic challenge.
• CD38/CD157: NAD+ases involved in calcium signalling and immune regulation, whose expression increases with age and inflammation — a major driver of age-related NAD+ decline.

Age-Related NAD+ Decline

Tissue NAD+ levels fall by approximately 50% between young adulthood and mid-life in humans, and this decline has been documented in skeletal muscle, liver, adipose tissue, and brain (Zhu et al., 2015; Mouchiroud et al., 2013). The mechanisms include increased CD38 activity driven by inflammaging, reduced biosynthesis from dietary precursors, and increased PARP activity from accumulated DNA damage.

Preclinical work in rodents demonstrated that restoring NAD+ via its precursors NMN and NR reversed several age-related physiological declines, including reduced muscle function, hepatic lipid accumulation, and cognitive performance (Mills et al., 2016; Yoshino et al., 2011). These findings drove interest in direct NAD+ administration as well as precursor supplementation.

Published Research Highlights

Human and translational research on NAD+ supplementation has grown substantially:

• Muscle and exercise physiology: Dolopikou et al. (2020) demonstrated that acute NR supplementation increased blood NAD+ and reduced fatigue markers in older adults performing eccentric exercise.
• Metabolic function: Remie et al. (2020) showed NR at 1,000 mg/day for 6 weeks increased skeletal muscle NAD+ by 40% in overweight men without adverse hepatic effects.
• Cardiovascular research: Dellinger et al. (2017) and subsequent trials demonstrated NMN and NR elevate circulating NAD+ in human subjects, with tolerability established across multiple cohorts.
• Neuroprotection: Preclinical models of Alzheimer's, Parkinson's, and ALS have shown NAD+ augmentation reduces neuroinflammation, improves mitochondrial function, and reduces neuronal loss (Hou et al., 2018).

Research Applications

NAD+ infusion protocols have been used in translational research contexts investigating withdrawal states, neurological function, and metabolic disease. The 500 mg intravenous vial format provides researchers with a controlled dose for in-vitro cellular studies examining direct NAD+ availability versus precursor conversion pathways — an important distinction given variability in NMN/NR conversion efficiency across cell types.

Stability and Handling

NAD+ is susceptible to hydrolysis, particularly in aqueous solution. Lyophilised (freeze-dried) powder maintains stability significantly longer than reconstituted solution. Reconstituted solutions should be used promptly or stored frozen. Avoid repeated freeze-thaw cycles. pH sensitivity is notable: NAD+ is stable in near-neutral pH (6–8) and degrades rapidly under acidic or alkaline conditions.

Stacking in Research Contexts

Researchers studying cellular energy metabolism often pair NAD+ precursors with compounds that activate downstream pathways. MOTS-C activates AMPK and SIRT1, two NAD+-dependent metabolic regulators. 5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), increasing available NAD+ precursor flux. These combinations are of interest in metabolic disease and obesity research models.